Skip to Content

Viatris Inc VTRS

Morningstar Rating
$13.26 +0.02 (0.15%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

VTRS is trading at a 2% premium.
Price
$13.26
Fair Value
$23.00
Uncertainty
Very High
1-Star Price
$43.67
5-Star Price
$3.90
Economic Moat
Fnns
Capital Allocation
Nwxrkwycn

Bulls Say, Bears Say

Bulls

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power.

Bears

Base business erosion will continue to persist in developed markets and act as headwinds that Viatris must try to offset with new product launches.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTRS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$13.24
Day Range
$13.1113.32
52-Week Range
$8.7413.42
Bid/Ask
$13.14 / $13.40
Market Cap
$15.91 Bil
Volume/Avg
9.0 Mil / 9.5 Mil

Key Statistics

Price/Earnings (Normalized)
4.04
Price/Sales
0.94
Dividend Yield (Trailing)
3.62%
Dividend Yield (Forward)
3.62%
Total Yield
5.17%

Company Profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
38,000

Competitors

Valuation

Metric
VTRS
TEVA
NVS
Price/Earnings (Normalized)
4.045.1514.55
Price/Book Value
0.691.974.34
Price/Sales
0.940.934.44
Price/Cash Flow
4.4310.2314.20
Price/Earnings
VTRS
TEVA
NVS

Financial Strength

Metric
VTRS
TEVA
NVS
Quick Ratio
0.780.540.88
Current Ratio
1.601.021.16
Interest Coverage
5.360.3910.94
Quick Ratio
VTRS
TEVA
NVS

Profitability

Metric
VTRS
TEVA
NVS
Return on Assets (Normalized)
7.36%6.70%12.15%
Return on Equity (Normalized)
17.56%39.00%27.10%
Return on Invested Capital (Normalized)
10.13%13.54%17.72%
Return on Assets
VTRS
TEVA
NVS
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ZTS
Zoetis Inc Class APlwp$86.3 Bil
MKKGY
Merck KGaA ADRPbckxvk$71.9 Bil
HLN
Haleon PLC ADRJmvc$37.8 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRBzbp$14.7 Bil
RDY
Dr Reddy's Laboratories Ltd ADRXgt$12.8 Bil
CTLT
Catalent IncGksrrz$10.5 Bil
PRGO
Perrigo Co PLCCzwj$4.3 Bil
CURLF
Curaleaf Holdings IncDrdg$3.7 Bil
PBH
Prestige Consumer Healthcare IncJdptfk$3.4 Bil

Sponsor Center